Anaphylaxis—a practice parameter update 2015

Phillip Lieberman; Richard A. Nicklas; Christopher Randolph; John Oppenheimer; David Bernstein; Jonathan Bernstein; Anne Ellis; David B K Golden; Paul Greenberger; Steven Kemp; David Khan; Dennis Ledford; Jay Lieberman; Dean Metcalfe; Anna Nowak-Wegrzyn; Scott Sicherer; Dana Wallace; Joann Blessing-Moore; David Lang; Jay M. Portnoy; Diane Schuller; Sheldon Spector; Stephen A. Tilles

doi:10.1016/j.anai.2015.07.019

Anaphylaxis—a practice parameter update 2015

Phillip Lieberman, Richard A. Nicklas, Christopher Randolph, John Oppenheimer, David Bernstein, Jonathan Bernstein, Anne Ellis, David B K Golden, Paul Greenberger, Steven Kemp, David Khan, Dennis Ledford, Jay Lieberman, Dean Metcalfe, Anna Nowak-Wegrzyn, Scott Sicherer, Dana Wallace, Joann Blessing-Moore, David Lang, Jay M. PortnoyDiane Schuller, Sheldon Spector, Stephen A. Tilles

Medicine, Allergy Division

Research output: Contribution to journal › Article › peer-review

303 Scopus citations

Original language	English (US)
Pages (from-to)	341-384
Number of pages	44
Journal	Annals of Allergy, Asthma and Immunology
Volume	115
Issue number	5
DOIs	https://doi.org/10.1016/j.anai.2015.07.019
State	Published - Nov 2015

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.anai.2015.07.019

Cite this

Lieberman, P., Nicklas, R. A., Randolph, C., Oppenheimer, J., Bernstein, D., Bernstein, J., Ellis, A., Golden, D. B. K., Greenberger, P., Kemp, S., Khan, D., Ledford, D., Lieberman, J., Metcalfe, D., Nowak-Wegrzyn, A., Sicherer, S., Wallace, D., Blessing-Moore, J., Lang, D., ... Tilles, S. A. (2015). Anaphylaxis—a practice parameter update 2015. Annals of Allergy, Asthma and Immunology, 115(5), 341-384. https://doi.org/10.1016/j.anai.2015.07.019

@article{68bd3a499fd441c2b449ccea1b429970,

title = "Anaphylaxis—a practice parameter update 2015",

author = "Phillip Lieberman and Nicklas, {Richard A.} and Christopher Randolph and John Oppenheimer and David Bernstein and Jonathan Bernstein and Anne Ellis and Golden, {David B K} and Paul Greenberger and Steven Kemp and David Khan and Dennis Ledford and Jay Lieberman and Dean Metcalfe and Anna Nowak-Wegrzyn and Scott Sicherer and Dana Wallace and Joann Blessing-Moore and David Lang and Portnoy, {Jay M.} and Diane Schuller and Sheldon Spector and Tilles, {Stephen A.}",

note = "Funding Information: Disclosures: The following is a summary of interests disclosed on work group members{\textquoteright} Conflict of Interest Disclosure Statements (not including information concerning family member interests). Completed Conflict of Interest Disclosure Statements are available upon request. David Bernstein, MD, is on the advisory boards of Teva and Circassion; is on the board of the American Board of Allergy and Immunology; is a consultant for Proctor & Gamble, Science Strategies, Guidepoint Federal, and Merck; provides legal support for Fowler, Whited, & Barrett; is speaker for Merck; and has received financial support from the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health (principal investigator) and Teva, Merck, Glaxo, Pfizer, Genentech, Novartis, Astra Zeneca, Amgon, Savoy, and Cephalon. Jonathan Bernstein, MD, has consulted for and received honorarium and gifts from Sanofi Aventis; served as consultant, speaker and researcher for Dyax, Shire, CSL Behring, ViroPharma, and research for Pharming, is the editor of the Journal of Asthma; serves on the AAAAI Board of Directors; is a committee member of the ACAAI, and is chair of the Allergists for Israel. Anne Ellis, MD, is s speaker for Pfizer Canada, Merck, and Astra; is on the advisory board of Palladin Labs; received a research grant from Circassia Ltd; and is on the Drug, Allergy & Anaphylaxis Committee of the ACAAI. David B.K. Golden, MD, is a consultant for Sanofi and GlaxoSmithKline, speaker for Genentech, and has received financial support from Siemens for a clinical trial. Paul Greenberger, MD, has consulted for Mylan (Day) and is a committee member of the Food and Drug Administration Pulmonary Allergy Drugs Advisory Committee. Kevin J. Kelly, MD, received research grants from Targacept, Merck Schering, Schering, Chiltern, and Glaxo; has consulted for the University of North Carolina; and is a leadership board member of the American Lung Association of Wisconsin. Steven Kemp, MD, is a committee member, assembly member, and speaker for the AAAAI; is an editorial board member and committee member of the ACAAI; and is on the board of directors for the American Board of Allergy & Immunology. David Khan, MD, is a speaker for Baxter and Genentech. Dennis Ledford, MD, is a speaker for the South Carolina Allergy & Immunology Society and Meda Pharmaceutical; has received research grants from Teva, Forest, Genentech, Merck, and ViroPharma; has consulted for Shook Hardy Bacon, Saieva and Stine, and Genentech; is on the advisory board of AstraZeneca. Jay Lieberman, MD, reports no conflicts. Philip Lieberman, MD, consults for Sanofi Aventis, Neyian, Merck, Genentech, Teva, Meda, and the Asthma and Allergy Foundation of America; serves on the advisory boards of Sanofi Aventis, Neyian, Merck, Teva, and Meda; and served as speaker for Neyina, Teva, and Meda. Dean Metcalfe, MD, reports no conflicts. Anna Nowak-Wegrzyn, MD, is on the advisory boards of Merck and Nutricia; has served as speaker for Thermofisher Scientific; and received a research grant from Nutucia. Scott Sicherer, MD, consults for Novartis; edits and receives honorarium from the Journal of Allergy and Clinical Immunology and is associate editor of the Journal of Allergy and Clinical Immunology In Practice; serves as speaker for and receives honorarium from the American Academy of Pediatrics; received honorarium from the American Board of Allergy and Immunology; is on the advisory board of Sanofi; edits and contributes to UpToDate; consults for the Food Allergy Initiative; received research grants from the National Institute of Allergy and Infectious Diseases, National Institutes of Health; is on the executive committee of the American Academy of Pediatrics; and is a medical advisor for the Food Allergy and Anaphylaxis Network and Food Allergy Research and Education. Dana Wallace, MD, is on the advisory board of Sanofi, Sunovion, and Mylan; serves as speaker for Sunovion, Teva, and Meda; and is on the board of directors of the World Allergy Organization. The Joint Task Force recognizes that experts in a field are likely to have interests that could come into conflict with development a completely unbiased and objective practice parameter. To take advantage of that expertise, a process has been developed to prevent potential conflicts from influencing the final document in a negative way. At the workgroup level, members who have a potential conflict of interest do not participate in discussions concerning topics related to the potential conflict; or if they do write a section on that topic, the workgroup completely rewrites it without their involvement to remove potential bias. In addition, the entire document is reviewed by the Joint Task Force and any apparent bias is removed at that level. Moreover, the practice parameter is sent for review by invited reviewers and by anyone with an interest in the topic by posting the document on the Web sites of the ACAAI and the AAAAI. Funding Information: This work was supported in part by the Division of Intramural Research, NIAID, National Institutes of Health. ",

year = "2015",

month = nov,

doi = "10.1016/j.anai.2015.07.019",

language = "English (US)",

volume = "115",

pages = "341--384",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

number = "5",

}

Lieberman, P, Nicklas, RA, Randolph, C, Oppenheimer, J, Bernstein, D, Bernstein, J, Ellis, A, Golden, DBK, Greenberger, P, Kemp, S, Khan, D, Ledford, D, Lieberman, J, Metcalfe, D, Nowak-Wegrzyn, A, Sicherer, S, Wallace, D, Blessing-Moore, J, Lang, D, Portnoy, JM, Schuller, D, Spector, S & Tilles, SA 2015, 'Anaphylaxis—a practice parameter update 2015', Annals of Allergy, Asthma and Immunology, vol. 115, no. 5, pp. 341-384. https://doi.org/10.1016/j.anai.2015.07.019

TY - JOUR

T1 - Anaphylaxis—a practice parameter update 2015

AU - Lieberman, Phillip

AU - Nicklas, Richard A.

AU - Randolph, Christopher

AU - Oppenheimer, John

AU - Bernstein, David

AU - Bernstein, Jonathan

AU - Ellis, Anne

AU - Golden, David B K

AU - Greenberger, Paul

AU - Kemp, Steven

AU - Khan, David

AU - Ledford, Dennis

AU - Lieberman, Jay

AU - Metcalfe, Dean

AU - Nowak-Wegrzyn, Anna

AU - Sicherer, Scott

AU - Wallace, Dana

AU - Blessing-Moore, Joann

AU - Lang, David

AU - Portnoy, Jay M.

AU - Schuller, Diane

AU - Spector, Sheldon

AU - Tilles, Stephen A.

N1 - Funding Information: Disclosures: The following is a summary of interests disclosed on work group members’ Conflict of Interest Disclosure Statements (not including information concerning family member interests). Completed Conflict of Interest Disclosure Statements are available upon request. David Bernstein, MD, is on the advisory boards of Teva and Circassion; is on the board of the American Board of Allergy and Immunology; is a consultant for Proctor & Gamble, Science Strategies, Guidepoint Federal, and Merck; provides legal support for Fowler, Whited, & Barrett; is speaker for Merck; and has received financial support from the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health (principal investigator) and Teva, Merck, Glaxo, Pfizer, Genentech, Novartis, Astra Zeneca, Amgon, Savoy, and Cephalon. Jonathan Bernstein, MD, has consulted for and received honorarium and gifts from Sanofi Aventis; served as consultant, speaker and researcher for Dyax, Shire, CSL Behring, ViroPharma, and research for Pharming, is the editor of the Journal of Asthma; serves on the AAAAI Board of Directors; is a committee member of the ACAAI, and is chair of the Allergists for Israel. Anne Ellis, MD, is s speaker for Pfizer Canada, Merck, and Astra; is on the advisory board of Palladin Labs; received a research grant from Circassia Ltd; and is on the Drug, Allergy & Anaphylaxis Committee of the ACAAI. David B.K. Golden, MD, is a consultant for Sanofi and GlaxoSmithKline, speaker for Genentech, and has received financial support from Siemens for a clinical trial. Paul Greenberger, MD, has consulted for Mylan (Day) and is a committee member of the Food and Drug Administration Pulmonary Allergy Drugs Advisory Committee. Kevin J. Kelly, MD, received research grants from Targacept, Merck Schering, Schering, Chiltern, and Glaxo; has consulted for the University of North Carolina; and is a leadership board member of the American Lung Association of Wisconsin. Steven Kemp, MD, is a committee member, assembly member, and speaker for the AAAAI; is an editorial board member and committee member of the ACAAI; and is on the board of directors for the American Board of Allergy & Immunology. David Khan, MD, is a speaker for Baxter and Genentech. Dennis Ledford, MD, is a speaker for the South Carolina Allergy & Immunology Society and Meda Pharmaceutical; has received research grants from Teva, Forest, Genentech, Merck, and ViroPharma; has consulted for Shook Hardy Bacon, Saieva and Stine, and Genentech; is on the advisory board of AstraZeneca. Jay Lieberman, MD, reports no conflicts. Philip Lieberman, MD, consults for Sanofi Aventis, Neyian, Merck, Genentech, Teva, Meda, and the Asthma and Allergy Foundation of America; serves on the advisory boards of Sanofi Aventis, Neyian, Merck, Teva, and Meda; and served as speaker for Neyina, Teva, and Meda. Dean Metcalfe, MD, reports no conflicts. Anna Nowak-Wegrzyn, MD, is on the advisory boards of Merck and Nutricia; has served as speaker for Thermofisher Scientific; and received a research grant from Nutucia. Scott Sicherer, MD, consults for Novartis; edits and receives honorarium from the Journal of Allergy and Clinical Immunology and is associate editor of the Journal of Allergy and Clinical Immunology In Practice; serves as speaker for and receives honorarium from the American Academy of Pediatrics; received honorarium from the American Board of Allergy and Immunology; is on the advisory board of Sanofi; edits and contributes to UpToDate; consults for the Food Allergy Initiative; received research grants from the National Institute of Allergy and Infectious Diseases, National Institutes of Health; is on the executive committee of the American Academy of Pediatrics; and is a medical advisor for the Food Allergy and Anaphylaxis Network and Food Allergy Research and Education. Dana Wallace, MD, is on the advisory board of Sanofi, Sunovion, and Mylan; serves as speaker for Sunovion, Teva, and Meda; and is on the board of directors of the World Allergy Organization. The Joint Task Force recognizes that experts in a field are likely to have interests that could come into conflict with development a completely unbiased and objective practice parameter. To take advantage of that expertise, a process has been developed to prevent potential conflicts from influencing the final document in a negative way. At the workgroup level, members who have a potential conflict of interest do not participate in discussions concerning topics related to the potential conflict; or if they do write a section on that topic, the workgroup completely rewrites it without their involvement to remove potential bias. In addition, the entire document is reviewed by the Joint Task Force and any apparent bias is removed at that level. Moreover, the practice parameter is sent for review by invited reviewers and by anyone with an interest in the topic by posting the document on the Web sites of the ACAAI and the AAAAI. Funding Information: This work was supported in part by the Division of Intramural Research, NIAID, National Institutes of Health.

PY - 2015/11

Y1 - 2015/11

UR - http://www.scopus.com/inward/record.url?scp=84956587094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956587094&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2015.07.019

DO - 10.1016/j.anai.2015.07.019

M3 - Article

C2 - 26505932

AN - SCOPUS:84956587094

SN - 1081-1206

VL - 115

SP - 341

EP - 384

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 5

ER -

Anaphylaxis—a practice parameter update 2015

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this